Brazil Antacids Market Overview, 2031

Key Insights

• According to the research report, "Brazil Antacids Market Outlook, 2031," published by Bonafide Research, the Brazil Antacids Market is expected to reach a market size of more than 318.9 Million by 2031.
• The Brazilian OTC antacids landscape is rapidly transitioning from traditional single-salt neutralizers (such as simple aluminum hydroxide or magnesium hydroxide) toward multi-action alginates and fast-acting effervescent delivery systems. Innovation in Brazil centers heavily on sodium alginate combined with dual antacid salts (pioneered by brands like Gaviscon Dual Action) and specialized mucosal protectors. Alginate-based formulations form a protective physical barrier over gastric contents while buffering acid, providing rapid relief for reflux symptoms exacerbated by Brazil's rich, meat-heavy regional diets.
• Urbanization, high dietary consumption of fatty/spicy foods, and workplace stress are key factors behind widespread heartburn and acid-related conditions across Brazil. Epidemiological data published by the Brazilian Federation of Gastroenterology (FBG) indicates that the global prevalence of heartburn at least once a week in the Brazilian urban population is 11.9%, with Gastroesophageal Reflux Disease (GERD) affecting approximately 7.3% of the population.
• Regulatory changes by ANVISA (Agência Nacional de Vigilância Sanitária) have simplified the registration and reclassification of non-prescription digestive remedies, enhancing consumer access. Brazil boasts an extensive retail pharmacy footprint of approximately 92,000 drugstore locations nationwide. Over-the-counter antacids and indigestion treatments benefit directly from this widespread retail access, serving as a first-line alternative to prescription drugs.

Market Outlook

• Manufacturers in Brazil are increasingly shifting focus toward single-dose liquid sachets, gel suspensions, and sugar-free chewables to cater to mobile urban workers. This convenient format innovation is expected to drive higher-margin sales in impulse pharmacy purchases across major metropolitan areas like São Paulo and Rio de Janeiro.
• Consumer interest in natural wellness is prompting top pharmaceutical players to develop hybrid antacids. Future offerings are combining fast-acting buffering agents with natural botanicals (e.g., boldo, camomile) and gut-health ingredients to offer combined immediate acidity buffering and long-term stomach-soothing benefits.
• Market standards and healthcare guidelines are governed by ANVISA (Agência Nacional de Vigilância Sanitária) alongside professional bodies like the FBG (Federação Brasileira de Gastroenterologia) and ABIMIP (Associação Brasileira da Indústria de Produtos de Medicamentos Isentos de Prescrição), while supply is led by major domestic and international players including Hypera Pharma (Estomazil, Epocler), Haleon (ENO), Reckitt Benckiser (Gaviscon), Bayer (Rennie), EMS Farmacêutica, and Eurofarma.

Market Dynamics

Driver: Rising digestive-health awareness and lifestyle-related gastrointestinal problems
A key driver for Brazil's antacids market is the increasing prevalence and awareness of digestive problems, combined with greater consumer understanding of gut health. Euromonitor reported that digestive remedies were one of Brazil's fastest-growing OTC categories in 2024, supported by stronger consumer awareness of gut health and the wider availability of products addressing specific digestive symptoms. It also expects antacids to maintain strong growth, partly because of low dietary quality among some consumers.
Challenge: Intense competition and substitution across digestive remedies
A major challenge is the high level of competition within and outside the antacid category. Brazilian consumers have access to antacids, H2 blockers, proton-pump inhibitors (PPIs), antiflatulents, digestive enzymes and other digestive remedies. Euromonitor specifically expects competition from both other digestive-remedy categories and products outside consumer health to limit stronger market growth. This makes differentiation difficult, particularly for basic antacid products where consumers may perceive limited differences between brands. Manufacturers must also compete for pharmacy shelf space and consumer visibility against a broad range of OTC products.
Trend: Expansion of new formats and digital pharmacy/e-commerce channels
The Brazilian antacids market is increasingly moving toward new product formats and more convenient purchasing channels. Euromonitor identifies new product formats as a contributor to antacid growth and highlights the importance of pharmacies as a distribution channel. An important development is the expansion of online pharmaceutical commerce. Mercado Livre has entered Brazil's pharmaceutical sector through the acquisition of Cuidamos Farma Ltda, which operates the Target drugstore network. Euromonitor views this as a development that could significantly influence pharmaceutical distribution.

Procurement and Industry Impact

• Brazil has a substantial pharmaceutical import requirement. World Bank WITS/UN Comtrade data show that Brazil imported approximately US$12.57 billion of pharmaceutical products in 2024. Major suppliers included the US (US$2.38 billion), Germany (US$1.73 billion), Switzerland (US$1.09 billion), Ireland (US$959 million) and India (US$582 million). For antacid manufacturers, this highlights the importance of securing reliable supplies of APIs, excipients and specialized pharmaceutical ingredients. Brazil's ANVISA requires regulatory controls for APIs and operates the CADIFA framework for API suitability.
• Brazil has a relatively rigorous regulatory environment for pharmaceutical inputs. ANVISA's API framework requires documentation and regulatory oversight of active ingredients, while imported pharmaceutical inputs are subject to sanitary controls. The CADIFA system provides a formal framework for demonstrating the suitability of APIs used in medicines. This means procurement cannot focus solely on the lowest-cost supplier. A supplier must also be capable of providing consistent quality, regulatory documentation, traceability and validated manufacturing processes.
• Pharmacies play a vital role in Brazil's digestive-remedies market, according to Euromonitor, while the broader pharmaceutical industry sold 6.07 billion packages in 2024. This creates significant opportunities for manufacturers able to achieve high production volumes and maintain competitive pricing. Procurement strategies will increasingly focus on API price negotiation, high-volume purchasing, packaging optimization and local/contract manufacturing. Scale efficiencies are particularly important because antacids compete in a price-sensitive OTC environment where retailers and consumers can readily compare competing products.

Segment Analysis

Brazil Antacids Market By Drug Class
• Acid neutralizers remain closely associated with rapid, symptom-oriented relief in Brazil because they directly neutralize gastric acid already present in the stomach. Aluminium hydroxide, magnesium-containing preparations and combination antacids are particularly relevant to this segment. Brazil's National Formulary includes aluminium hydroxide suspension as an antacid preparation, while Anvisa maintains a formal list of medicines exempt from prescription (MIPs), supporting the role of self-care products in pharmacy-based treatment.
• Proton Pump Inhibitors (PPIs) occupy a different position because they suppress acid production rather than neutralizing acid already present. Their relevance is stronger for recurring dyspeptic or reflux symptoms where consumers move beyond occasional relief. A Brazilian primary-care survey of 719 individuals found PPIs were the most frequently self-medicated gastrointestinal drug class, accounting for 67% of medications used for digestive-symptom self-treatment. This illustrates the strong connection between recurring symptoms and acid-suppression therapy in Brazil.
• H2 antagonists provide another method of reducing gastric acid secretion and can serve consumers seeking an alternative to PPIs. Their role is particularly relevant in episodic or mild acid-related symptoms. However, they compete with both inexpensive conventional antacids and the stronger acid-suppression positioning of PPIs, making pharmacist guidance and symptom frequency important factors in product selection.
• Pro-motility agents form a more specialized gastrointestinal segment because their principal action is directed toward gastrointestinal movement and gastric emptying rather than acid neutralization. They can be relevant when reflux or upper-GI discomfort occurs alongside delayed gastric emptying, fullness or other motility-related symptoms. Consequently, their use is more clinically oriented than conventional Brazilian antacid self-treatment.
• Combination formulations have particular potential because Brazilian consumers may describe several overlapping complaints simply as acidity, including heartburn, indigestion, bloating and gas. Combining an antacid with alginate, simethicone or another gastrointestinal ingredient allows manufacturers to address multiple symptoms in one product. This is consistent with Brazil's established use of multi-ingredient gastrointestinal formulations and the regulatory recognition of antacids combined with antiflatulent or carminative ingredients.

Brazil Antacids Market By Dosage Form
• Tablets and chewables provide a convenient format for Brazil's self-care environment because they are portable, require no measuring equipment and can be taken immediately after symptoms occur. Chewables are particularly suitable for consumers seeking relief after meals or while away from home. Their unit-based dosing also makes them convenient for retail-pharmacy recommendation.
• Liquid suspensions remain an established dosage-form option because they can accommodate relatively high quantities of antacid ingredients and are suitable for consumers who dislike swallowing tablets. The Brazilian Pharmacopeia's National Form includes a standardized aluminium hydroxide suspension, specifying agitation before use and measured administration. This demonstrates the established pharmaceutical infrastructure behind liquid antacid formulations in Brazil.
• Powders offer a flexible alternative to ready-made tablets and liquids and can be designed as single-dose sachets or preparations requiring dissolution or dispersion. Their portability can be attractive in Brazil's consumer self-care market, although moisture protection and clear preparation instructions are important for maintaining product quality.
• Gels and syrups emphasize smooth administration and can provide a more comfortable alternative for consumers who dislike solid dosage forms. Gel-like formulations can also support alginate-based reflux-barrier concepts, while syrup-style products can differentiate through flavour and sensory characteristics. Brazil's established use of liquid aluminium hydroxide preparations provides a foundation for this broader liquid/semi-solid segment.
• Gummies and other formats represent a more consumer-oriented opportunity rather than a traditional Brazilian antacid format. Gummies can improve portability and palatability, but conventional antacid ingredients may require relatively large quantities, creating challenges around taste, texture and active-ingredient loading. Effervescent preparations and rapidly dispersible formats provide alternative opportunities for manufacturers seeking convenience-focused differentiation.

Brazil Antacids Market By Indication
• Gastroesophageal Reflux Disease (GERD) represents an important indication for Brazil's acid-control category because recurrent reflux symptoms can move consumers from occasional antacid use toward longer-duration acid suppression. Brazilian gastroenterology research has documented substantial reflux-related symptom burden, while treatment choice increasingly depends on symptom frequency and severity. The distinction between occasional reflux and established GERD is particularly important because repeated self-treatment can mask symptoms requiring medical assessment.
• Heartburn is a strong consumer-facing indication because it is readily recognizable and frequently encourages direct pharmacy purchases. Brazilian self-medication research demonstrates the broader importance of treating digestive symptoms outside formal medical consultations. In a primary-care survey of 719 people, 28.7% reported self-medication to control digestive symptoms; among these cases, 91.8% were related to dyspeptic complaints. Antacids represented 15% of the medications used, showing their continuing role alongside PPIs and other therapies.
• Peptic ulcer represents a more medically managed indication than routine heartburn. Antacids may reduce acid-related discomfort, but appropriate ulcer treatment generally requires identification and management of underlying causes such as H. pylori infection or NSAID-associated mucosal injury. PPIs therefore have a more important therapeutic role in ulcer healing, while conventional antacids remain primarily positioned for symptomatic relief.
• Others include dyspepsia, acid indigestion, epigastric discomfort, gastritis-related symptoms and post-meal digestive complaints. This segment is particularly significant in Brazil because consumers may use broad terms such as indigestion or acidity rather than a specific clinical diagnosis. The high level of digestive-symptom self-medication observed in Brazilian primary care illustrates the breadth of this symptom-led segment.

Brazil Antacids Market By Distribution Channel
• Retail pharmacies remain the central channel for consumer access because Brazil has a well-established MIP framework. Anvisa defines MIPs as medicines that can be dispensed without a prescription and states that they are available for self-service in pharmacies and drugstores. This structure supports symptom-driven purchases of appropriately classified antacid products while retaining pharmaceutical quality, safety and efficacy requirements.
• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, peptic ulcers, severe dyspepsia and other gastrointestinal disorders. Purchasing in this channel is therefore influenced more by physician diagnosis, hospital treatment protocols and medication management than by spontaneous OTC demand. PPIs and other acid-suppressive medicines are particularly relevant in hospital-based treatment.
• Online pharmacies / E-commerce provide convenience for repeat purchases and enable consumers to compare brands, dosage forms and pack sizes. This channel can be particularly useful for consumers already familiar with a specific antacid product. However, Brazilian online medicine sales remain subject to Anvisa's medicine classification and regulatory requirements, meaning products classified as MIPs and prescription medicines are treated differently.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce